LatestIP And Trademarks 15 October 2026
Godavari Secures US Patent for Cancer
Indian biotech firm Godavari Biorefineries has been granted a United States patent for the compound 5‑Hydroxy‑1,4‑Naphthalenedione, which has shown ability to inhibit cancer stem cells in pre‑clinical studies, specifically targeting breast and prostate cancers. The patent strengthens the company's IP portfolio and could accelerate development of new oncology therapies.
Godavari Biorefineries, an Indian biotech company, secured a U.S. patent for the experimental compound 5‑Hydroxy‑1,4‑Naphthalenedione that targets cancer stem cells. The patent filing was reported by ScanX.
- Inhibits stem cells linked to breast cancer and prostate cancer in laboratory studies.
- Expands Godavari's intellectual‑property portfolio and may speed up oncology drug development.
- Positions the firm for potential collaborations or licensing deals in the U.S. market.
Need help understanding this update?
Connect with our domain experts instantly via WhatsApp for customized legal guidance.